Pfizer has released the official results of its COVID-19 vaccine clinical trials in kids aged 5 to 11, indicating that the vaccination causes a ‘safe’ and ‘strong’ immune response in this age range.
According to the facts, Pfizer’s COVID-19 vaccine protects children aged 5 to 11 from symptomatic Coronavirus infection 90.7 percent of the time.
In the highly anticipated clinical studies, the New York-based pharmaceutical business has enrolled 2,268 children between the ages of 5 and 11. All of the subjects received two 10-microgram doses of Pfizer’s coronavirus vaccine 21 days apart.
Read more: Pfizer COVID-19 vaccine could soon be approved for children ages 5-11
Pfizer carefully opted a 10-microgram dose in these trials to test the vaccine’s safety and efficacy in kids aged 5 to 11, as it had previously delivered a 30-microgram dose in clinical trials of children aged 12 to 15.
The immune responses of all 2,268 children were assessed by comparing the levels of neutralizing antibodies in their blood to those of a control group of 16 to 25-year-olds who had received the two dosages higher than 30-microgram.
Pfizer was given permission to use the drug in individuals aged 16 and up at first. It was later approved for usage among children aged 12 to 15. It now hopes to gain regulatory permission for usage in children aged 5 to 11 years old. Pfizer’s next goal is to get approval for its Coronavirus vaccine to be used in infants as young as six months old.
On the other hand, the US Food and Drug Administration (FDA) will meet on Tuesday to decide whether to issue Pfizer’s vaccine for children aged 5 to 11 an Emergency Use Authorization (EUA).
If the FDA approves Pfizer’s vaccine for children aged 5 to 11, the US Centers for Disease Control and Prevention (CDC) will meet on November 2-3 to provide recommendations to the FDA on how the vaccine should be administered to children in that age group. Because most US states wait for the CDC’s FDA recommendations before providing any vaccine to their citizens.
